Servier

Contact
servier.fr
+33155726000

Servier

22 rue Garnier
92578 Neuilly-sur-Seine
France
+33155726000
servier.fr
Contact
Profile News
Contact

About Servier

Servier is the leading independent French pharmaceutical company, established in 1954 by its founder, Jacques Servier, M.D., Pharm.D. The group is established in 140 countries and 82% of Servier products are prescribed out of France. Sales turnover in 2006 rose to 3.3 billion euros. Almost 25% of Servier's turnover is invested in Research and Development. The Servier Group counts 19 International Centers of Therapeutic Research, and its principal therapeutic research orientations are cardiovascular diseases, diabetes, neuropsychiatric disorders, cancer, and osteoarticular diseases.

Read more about Servier
Facts about Servier
  • Focus : Manufacturer
  • Industry : Pharma

News about Servier

Servier

03-Sep-2018 | business & finance

Servier finalizes acquisition of Shire’s oncology branch

Servier announced that it has finalized the previously announced acquisition of Shire’s oncology branch after obtaining regulatory clearance. The 2.4 ...

Read news
Servier

25-Jul-2012 | business & finance

Galapagos delivers candidate drug in osteoarthritis alliance with Servier

Galapagos NV announced that it has identified the first pre-clinical candidate compound in its osteoarthritis alliance with Servier.  The compound inhibits ...

Read news
Servier

11-Oct-2011 | business & finance

Servier and Galapagos initiate strategic alliance for innovative treatments in oncology

Joint discovery and development of novel small molecule therapies for cancer

Read news
Servier

11-Oct-2011 | business & finance

Hybrigenics and Servier enter into a licence and research collaboration agreement in oncology and other therapeutic fields

Hybrigenics will receive EUR four million over three years to identify new deubiquitinating enzymes and screen their inhibitors, and is further eligible to success milestones

Read news
Servier

10-Feb-2011 | business & finance

Galapagos receives €4 million in milestones from Servier

Galapagos NV  announced that it reached milestones in its osteoarthritis alliance with Servier, resulting in payments in 2010 revenues totaling €4 ...

Read news
Servier

02-Jul-2010 | business & finance

Servier and Galapagos initiate strategic alliance in osteoarthritis

Servier and Galapagos NV announced that they have entered into a multi-year strategic alliance to develop new therapies in osteoarthritis (OA). The allia ...

Read news
Servier

21-Jan-2010 | science

Largest academic-industry collaboration for drug discovery in depression and schizophrenia launched

An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic- ...

Read news
Servier

02-Sep-2008 | research and development

Procoralan (ivabradine) is Shown to Reduce Myocardial Infarction and Revascularisation in Stable Coronary Patients

The results of the BEAUTIFUL (morBidity-mortality EvAlUaTion of the IF inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial ...

Read news
Show more news about Servier

Here you will find Servier